Overview

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of > 33% hepatic steatosis or nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. Patients who have not been previously treated for hepatitis C (treatment naive) will be enrolled.
Phase:
Phase 4
Details
Lead Sponsor:
Brooke Army Medical Center
Collaborators:
Hoffmann-La Roche
The Geneva Foundation
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Orlistat
Peginterferon alfa-2a
Ribavirin